pdgfa Search Results


pdgfa  (Gold Biotechnology Inc)
90
Gold Biotechnology Inc pdgfa
Pdgfa, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdgfa/product/Gold Biotechnology Inc
Average 90 stars, based on 1 article reviews
pdgfa - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
8 hyd roxy deoxy guano sine 8 ohdg  (Shanghai Korain Biotech Co Ltd)
93
Shanghai Korain Biotech Co Ltd 8 hyd roxy deoxy guano sine 8 ohdg
8 Hyd Roxy Deoxy Guano Sine 8 Ohdg, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/8 hyd roxy deoxy guano sine 8 ohdg/product/Shanghai Korain Biotech Co Ltd
Average 93 stars, based on 1 article reviews
8 hyd roxy deoxy guano sine 8 ohdg - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
recombinant mouse pdgfa  (Novus Biologicals)
91
Novus Biologicals recombinant mouse pdgfa
Recombinant Mouse Pdgfa, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse pdgfa/product/Novus Biologicals
Average 91 stars, based on 1 article reviews
recombinant mouse pdgfa - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
human growth factors  (Proteintech)
93
Proteintech human growth factors
Human Growth Factors, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human growth factors/product/Proteintech
Average 93 stars, based on 1 article reviews
human growth factors - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
pdgf a  (Novus Biologicals)
86
Novus Biologicals pdgf a
Pdgf A, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdgf a/product/Novus Biologicals
Average 86 stars, based on 1 article reviews
pdgf a - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
gene exp pdgfa mm00435540 m1  (Thermo Fisher)
85
Thermo Fisher gene exp pdgfa mm00435540 m1
Gene Exp Pdgfa Mm00435540 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pdgfa mm00435540 m1/product/Thermo Fisher
Average 85 stars, based on 1 article reviews
gene exp pdgfa mm00435540 m1 - by Bioz Stars, 2026-05
85/100 stars
  Buy from Supplier
gene exp pdgfa mm01205760 m1  (Thermo Fisher)
99
Thermo Fisher gene exp pdgfa mm01205760 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Mm01205760 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pdgfa mm01205760 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp pdgfa mm01205760 m1 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
gene exp pdgfa hs00964426 m1  (Thermo Fisher)
97
Thermo Fisher gene exp pdgfa hs00964426 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Hs00964426 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pdgfa hs00964426 m1/product/Thermo Fisher
Average 97 stars, based on 1 article reviews
gene exp pdgfa hs00964426 m1 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
gene exp pdgfa hs00234994 m1  (Thermo Fisher)
91
Thermo Fisher gene exp pdgfa hs00234994 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Hs00234994 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pdgfa hs00234994 m1/product/Thermo Fisher
Average 91 stars, based on 1 article reviews
gene exp pdgfa hs00234994 m1 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
gene exp pdgfa hs00236997 m1  (Thermo Fisher)
90
Thermo Fisher gene exp pdgfa hs00236997 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Hs00236997 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pdgfa hs00236997 m1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
gene exp pdgfa hs00236997 m1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
pdgfa  (OriGene)
90
OriGene pdgfa
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Pdgfa, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdgfa/product/OriGene
Average 90 stars, based on 1 article reviews
pdgfa - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Cell Culture, Derivative Assay, Migration, Wound Healing Assay, Expressing, Produced, Control

Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Derivative Assay, Gene Expression, Expressing, Muscles

Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Cell Culture, Derivative Assay, Migration, Wound Healing Assay, Expressing, Produced, Control

Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Derivative Assay, Gene Expression, Expressing, Muscles